Letter

Risk of gastrointestinal effects with COX-2 inhibitors and NSAIDs: How strong is the evidence?

BMJ 2005; 331 doi: 10.1136/bmj.331.7530.1474 (Published 15 December 2005)
Cite this as: BMJ 2005;331:1474.1

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Bernard G Bannwarth, professor of therapeutics (bernard.bannwarth@u-bordeaux2.fr)
  1. University Hospital, 33076 Bordeaux, France

    EDITOR—The major conclusion drawn from the nested case-control study by Hippisley-Cox et al was that no consistent evidence was found of enhanced safety against gastrointestinal events with any of the new cyclo-oxygenase-2 (COX-2) inhibitors compared with non-selective non-steroidal anti-inflammatory …

    Access to the full text of this article requires a subscription or payment

    Subscribe

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    Rapid responses

    THIS WEEK'S POLL

    Read related article

    See previous polls

    BMJ most popular